Nanolynx is developing conditionally active nanobody-drug conjugates that overcome the tissue penetration and toxicity limits of conventional ADCs, enabling safer and more efficacious therapies for hard-to-treat cancers.
Nanolynx is developing conditionally active nanobody-drug conjugates that overcome the tissue penetration and toxicity limits of conventional ADCs, enabling safer and more efficacious therapies for hard-to-treat cancers.
Wirtsgartenweg 44, 4123 Allschwil, Switzerland